Episode # 327 • 01 Sept 2026
Clinical Approaches to Testicular Cancer Management
What are the key considerations for choosing between surveillance, surgery, and chemotherapy in testicular cancer? On this episode of BackTable Urology, host Dr. Rich Matulewicz is joined by Dr. Sean Kern and Dr. Sam Funt for an in-depth discussion on clinical approaches to testicular cancer. They start with a real-world case, reviewing initial evaluation, imaging, tumor markers, and counseling on fertility, body image, and hypogonadism. The conversation highlights how nuanced patient selection influences decisions between surveillance, surgical intervention, and adjuvant chemotherapy.
Timestamps
00:00 - Introduction
01:40 - Initial Case Workup and Counseling
06:28 - Why Testicular Cancer Happens
09:17 - Management Considerations with Post-Orchiectomy Pathology
19:21 - RPLND Benefits and Drawbacks
23:39 - Surveillance Schedule and Long Term Follow Up
28:17 - Second Tumor Risk
30:36 - Evolving Seminoma Treatment
37:57 - RPLND Selection Factors
40:10 - Adjuvant Chemo Debate and Pathology
46:06 - Closing Takeaways
Resources
You may also like
More about this episode
The episode explores postoperative management, including long-term surveillance, risk of a second tumor, and strategies for lifelong follow-up. The doctors discuss evolving practice in the management of low-volume stage II seminoma, the increasing use of RPLND to reduce chemo and radiation exposure, and the importance of extended patient counseling over multiple visits. The discussion emphasizes individualized care, the role of new diagnostics, and the need for reassurance and support throughout the treatment journey.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.